SUNNYVALE, Calif.--(BUSINESS WIRE)--Labcyte, a company revolutionizing life science research with its patented acoustic liquid handling technology, today praised the results of an international collaboration between the Institute for Molecular Medicine Finland (FIMM), University of Helsinki and the pharmaceutical company Pfizer. The research, described on 9 February, 2015, in the journal Nature1, identified a previously unrecognized action of Pfizer’s axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
